Literature DB >> 1380181

A critical role for conserved residues in the cleft of HLA-A2 in presentation of a nonapeptide to T cells.

F Latron1, L Pazmany, J Morrison, R Moots, M A Saper, A McMichael, J L Strominger.   

Abstract

The peptide binding cleft of the class I human histocompatibility antigen, HLA-A2, contains conserved amino acid residues clustered in the two ends of the cleft in pockets A and F as well as polymorphic residues. The function of two conserved tyrosines in the A pocket was investigated by mutating them to phenylalanines and of a conserved tyrosine and threonine in the F pocket by mutating them to phenylalanine and valine, respectively. Presentation of influenza virus peptides and of intact virus to cytolytic T lymphocytes (CTLs) was then examined. The magnitude of the reduction seen by the mutation of the two tyrosines in the A pocket suggests that hydrogen bonds involving them have a critical function in the binding of the NH2-terminal NH3+ of the peptide nonamer and possibly of all bound peptide nonamers. In contrast, the mutations in the F pocket had no effect on CTL recognition.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380181     DOI: 10.1126/science.1380181

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  14 in total

1.  A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.

Authors:  P A Goepfert; A Bansal; B H Edwards; G D Ritter; I Tellez; S A McPherson; S Sabbaj; M J Mulligan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Mutations inside but not outside the peptide binding cleft of the H-2 Ld molecule affect CTL recognition and binding of the nucleoprotein peptide from the lymphocytic choriomeningitis virus.

Authors:  C E Hioe; D M McKinney; J A Frelinger; M McMillan
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

Review 3.  Modulation of the immune response with T-cell epitopes: the ultimate goal for specific immunotherapy of autoimmune disease.

Authors:  P J Fairchild; C J Thorpe; P J Travers; D C Wraith
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

4.  MHC class I polymorphism in lupus-prone MRL/Mp mice.

Authors:  S L Peng; J Craft
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

5.  MHC class II molecules and the immune response to the ABBOS peptide of bovine serum albumin: prelude to type 1 (insulin-dependent) diabetes?

Authors:  G K Papadopoulos
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

6.  Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein.

Authors:  A Bertoletti; F V Chisari; A Penna; S Guilhot; L Galati; G Missale; P Fowler; H J Schlicht; A Vitiello; R C Chesnut
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

7.  A subset of HLA-B27 molecules contains peptides much longer than nonamers.

Authors:  R G Urban; R M Chicz; W S Lane; J L Strominger; A Rehm; M J Kenter; F G UytdeHaag; H Ploegh; B Uchanska-Ziegler; A Ziegler
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

8.  Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigen.

Authors:  D Rognan; L Scapozza; G Folkers; A Daser
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

9.  Thermal Stability of Heterotrimeric pMHC Proteins as Determined by Circular Dichroism Spectroscopy.

Authors:  Anna Fuller; Aaron Wall; Michael D Crowther; Angharad Lloyd; Alexei Zhurov; Andrew K Sewell; David K Cole; Konrad Beck
Journal:  Bio Protoc       Date:  2017-07-05

10.  A novel type of class I gene organization in vertebrates: a large family of non-MHC-linked class I genes is expressed at the RNA level in the amphibian Xenopus.

Authors:  M F Flajnik; M Kasahara; B P Shum; L Salter-Cid; E Taylor; L Du Pasquier
Journal:  EMBO J       Date:  1993-11       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.